Houston organization doles out over $775,000 in prizes to women-led health tech startups

and the winner is

Mara McFadden (left), CEO of Endolumik, took home the top prize at the Ignite Fire Pitch Competition. Photo courtesy of Ignite

After virtual and postponed events, Ignite Healthcare Network finally got to honor its 2021 cohort and name the annual winners.

The Fifth Annual Fire Pitch Competition was slated to take place last November, but was postponed to January. Affected by the Delta and then Omicron variants of COVID-19, the event finally got to return to in-person networking and pitches on Thursday, March 3.

"The opportunity to bring people together is a really different level of engagement and energy," Ayse McCracken, founder and board chair of Ignite, says ahead of the awards event. "We love seeing the energy that's being generated in Houston around innovation — and particularly health care innovation."

Seven companies pitched and three were awarded monetary prizes. Morgantown, West Virginia-based Endolumik, which has developed a patent-pending fluorescence-guided device to improve visualization and safety of robotic and laparoscopic bariatric operations, took home the top prize, which included a total of $500,000 in investment prizes from the Texas Medical Center Venture Fund and Wavemaker Three-Sixty Health.

Second place was awarded to Rx Bandz of Locust Valley, New York. The company created the MiniJect, the world’s smallest military-grade auto-injector designed to deliver a wide range of injectable medication, and was awarded $250,000 from the Texas Halo Fund and $25,000 from The Southwest National Pediatric Device Innovation Consortium.

San Antonio-based Hera Biotech took third place and was awarded a pilot program prize with Banner Health. Hera has developed the first non-surgical, tissue-based test capable of diagnosing endometriosis.

Ignite taps into Houston health care institutions to provide opportunities for its cohort of companies. According to a news release, this year’s partner organizations included Houston Methodist, Memorial Hermann Health System, Texas Children’s Hospital, Texas Children’s Pediatrics, The Menninger Clinic, Banner Health, Kindred Healthcare, Aetna, Commonwealth Care Alliance, BLUE KC, Hospital for Special Surgery, Summit Health, TMC Ventures, Texas Heart Institute, Golden Seeds, Portfolia, The Artemis Fund, Wavemaker 360 Health, Prosalus Capital Partners, 7Wire Ventures, Texas Halo Fund, Unity Point Ventures and others.

The judges who evaluated the competition’s panel of companies included:

  • Jay Goss, MBA General Partner, Wavemaker Three-Sixty Health
  • Amanda Hammel, Chief Information Officer, Memorial Hermann Health System
  • Karen Hill, MD, MBA, SVP and Chief Medical Officer, Texas Children’s Health Plan
  • Tom Luby, PhD, Director, Texas Medical Center Innovation Institute
  • Fiona Mack, PhD, Head of JLABS @TMC
  • Roberta Schwartz, PhD, EVP and Chief Innovation Officer, Houston Methodist Hospital
  • Andrew Truscott, Global Health Technology Lead, Accenture
Ria Health took home first place at the third annual Fire Pitch Competition. Courtesy of Ignite Healthcare

Female founders win big at this Houston health tech pitch competition

pitch perfect

All it takes is a spark for something to ignite, and, at the third annual Fire Pitch Competition by the Ignite Healthcare Network, eight female founders set the stage on fire.

The Fire Pitch Competition first started in 2017 to shine a spotlight on female entrepreneurs in health care. With two successful events under her belt, Ayse McCracken says she knew she could do more to help these women with their business ideas.

"What we discovered is that it's not enough. Startups get to pitch all over, and they want to invest their time wisely," McCracken says. "And it's not enough for the rest of the ecosystem — the customers — and the investors want companies that actually are investable."

So, this summer, McCracken and her team launched a mini accelerator. Thirteen companies participated in the Fire Pitch Customer-Partner Program that matched the companies with potential customers, pilot opportunities, and more. Participating customer organizations have included Humana, Houston Methodist, Memorial Hermann Health System, Gallagher, Texas Children's Hospital, Texas Children's Pediatrics, DePelchin, Next Level Urgent Care, University of Houston College of Medicine, VillageMD, and The Menninger Clinic.

Then, eight finalists of the group were selected to go on to pitch at the Fire Pitch.

Also new this year: More cash prizes. In previous years, the Fire Pitch has around $20,000 on the table. This year's awards doled out $265,000 in cash and investment prizes to six of the eight companies that pitched. The panel of five judges included: Babs Carryer, entrepreneur, and director of Big Idea Center for the University of Pittsburgh's Innovation Institute; Tom Luby, director of the Texas Medical Center Innovation Institute; Kerry Rupp, partner at True Wealth Ventures; Sarah Sossong, principal at Flare Capital Partners; and Andrew Truscott, managing director for Health and Public Service at Accenture.

Here's which companies took home prizes at the 2019 Fire Pitch Competition at the Texas Medical Center's Innovation Institute on October 17.

First place: Ria Health

Ria Health, a San Francisco-based elemental health practice that uses technology and care to provide treatment for Alcohol Use Disorder, was the big winner at the pitch event.

Jen Douglas, CFO of the company, took home first place and the $15,000 prize from Ignite Healthcare Network, but the company also snagged one of the new awards this year. The Texas Medical Center's Innovation Institute awarded Ria Health with a $50,000 investment prize. Ria Health previously participated in the TMCx08 digital health cohort, so the team is very familiar with Houston and the TMC.

Second place: SoundScouts

Sydney, Australia-based SoundScouts is on a mission to help early detection of hearing in school aged children. Carolyn Mee, founder and CEO, represented the company on the stage. She took home second place, which didn't come with an investment or cash prize.

Third place: Savonix

Savonix also didn't walk away with any money, but was recognized by the judges for founder and CEO Mylea Charvet's pitch. The San Francisco-based company is a digital cognitive assessment platform that can easily and cheaply gauge cognitive function.

Texas Halo Fund $100,000 award: PATH EX

The biggest winner of the night based on investment size was Houston-based PATH EX. Led by CEO and co-founder, Sinead Miller, PATH EX has a solution to hospitals' biggest killers: Sepsis. The current TMCx company has a unique pathogen extraction platform that can directly capture and eradicate bacteria.

Miller accepted a new award for this year's program that came with a $100,000 investment from the Texas Halo Fund.

Texas Halo Fund $50,000 award: PyrAmes 

One award wasn't enough for the Texas Halo Fund, which handed out a second new award to Cupertino, California-based PyrAmes. Presented by co-founder and CTO, Xina Quan, the company has created a wearable blood pressure monitor that is reliable and nonintrusive to patients. Quan accepted the $50,000 investment from the fund.

Houston Angel Network $50,000 award: Materna Medical 

San Francisco-base Materna Medical, which created a device to help protect and prepare expecting mothers' pelvic health ahead of childbirth, took home the last investment prize. President and CEO Tracy MacNeal presented the company and accepted the Houston Angel Network's $50,000 award.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston hospital names leading cancer scientist as new academic head

new hire

Houston Methodist Academic Institute has named cancer clinician and scientist Dr. Jenny Chang as its new executive vice president, president, CEO, and chief academic officer.

Chang was selected following a national search and will succeed Dr. H. Dirk Sostman, who will retire in February after 20 years of leadership. Chang is the director of the Houston Methodist Dr. Mary and Ron Neal Cancer Center and the Emily Herrmann Presidential Distinguished Chair in Cancer Research. She has been with Houston Methodist for 15 years.

Over the last five years, Chang has served as the institute’s chief clinical science officer and is credited with strengthening cancer clinical trials. Her work has focused on therapy-resistant cancer stem cells and their treatment, particularly relating to breast cancer.

Her work has generated more than $35 million in funding for Houston Methodist from organizations like the National Institutes of Health and the National Cancer Institute, according to the health care system. In 2021, Dr. Mary Neal and her husband Ron Neal, whom the cancer center is now named after, donated $25 million to support her and her team’s research on advanced cancer therapy.

In her new role, Chang will work to expand clinical and translational research and education across Houston Methodist in digital health, robotics and bioengineered therapeutics.

“Dr. Chang’s dedication to Houston Methodist is unparalleled,” Dr. Marc L. Boom, Houston Methodist president and CEO, said in a news release. “She is committed to our mission and to helping our patients, and her clinical expertise, research innovation and health care leadership make her the ideal choice for leading our academic mission into an exciting new chapter.”

Chang is a member of the American Association of Cancer Research (AACR) Stand Up to Cancer Scientific Advisory Council. She earned her medical degree from Cambridge University in England and completed fellowship training in medical oncology at the Royal Marsden Hospital/Institute for Cancer Research. She earned her research doctorate from the University of London.

She is also a professor at Weill Cornell Medical School, which is affiliated with the Houston Methodist Academic Institute.

Texas A&M awarded $1.3M federal grant to develop clean energy tech from electronic waste

seeing green

Texas A&M University in College Station has received a nearly $1.3 million federal grant for development of clean energy technology.

The university will use the $1,280,553 grant from the U.S. Department of Energy to develop a cost-effective, sustainable method for extracting rare earth elements from electronic waste.

Rare earth elements (REEs) are a set of 17 metallic elements.

“REEs are essential components of more than 200 products, especially high-tech consumer products, such as cellular telephones, computer hard drives, electric and hybrid vehicles, and flat-screen monitors and televisions,” according to the Eos news website.

REEs also are found in defense equipment and technology such as electronic displays, guidance systems, lasers, and radar and sonar systems, says Eos.

The grant awarded to Texas A&M was among $17 million in DOE grants given to 14 projects that seek to accelerate innovation in the critical materials sector. The federal Energy Act of 2020 defines a critical material — such as aluminum, cobalt, copper, lithium, magnesium, nickel, and platinum — as a substance that faces a high risk of supply chain disruption and “serves an essential function” in the energy sector.

“DOE is helping reduce the nation’s dependence on foreign supply chains through innovative solutions that will tap domestic sources of the critical materials needed for next-generation technologies,” says U.S. Energy Secretary Jennifer Granholm. “These investments — part of our industrial strategy — will keep America’s growing manufacturing industry competitive while delivering economic benefits to communities nationwide.”

------

This article originally appeared on EnergyCapital.

Biosciences startup becomes Texas' first decacorn after latest funding

A Dallas-based biosciences startup whose backers include millionaire investors from Austin and Dallas has reached decacorn status — a valuation of at least $10 billion — after hauling in a series C funding round of $200 million, the company announced this month. Colossal Biosciences is reportedly the first Texas startup to rise to the decacorn level.

Colossal, which specializes in genetic engineering technology designed to bring back or protect various species, received the $200 million from TWG Global, an investment conglomerate led by billionaire investors Mark Walter and Thomas Tull. Walter is part owner of Major League Baseball’s Los Angeles Dodgers, and Tull is part owner of the NFL’s Pittsburgh Steelers.

Among the projects Colossal is tackling is the resurrection of three extinct animals — the dodo bird, Tasmanian tiger and woolly mammoth — through the use of DNA and genomics.

The latest round of funding values Colossal at $10.2 billion. Since launching in 2021, the startup has raised $435 million in venture capital.

In addition to Walter and Tull, Colossal’s investors include prominent video game developer Richard Garriott of Austin and private equity veteran Victor Vescov of Dallas. The two millionaires are known for their exploits as undersea explorers and tourist astronauts.

Aside from Colossal’s ties to Dallas and Austin, the startup has a Houston connection.

The company teamed up with Baylor College of Medicine researcher Paul Ling to develop a vaccine for elephant endotheliotropic herpesvirus (EEHV), the deadliest disease among young elephants. In partnership with the Houston Zoo, Ling’s lab at the Baylor College of Medicine has set up a research program that focuses on diagnosing and treating EEHV, and on coming up with a vaccine to protect elephants against the disease. Ling and the BCMe are members of the North American EEHV Advisory Group.

Colossal operates research labs Dallas, Boston and Melbourne, Australia.

“Colossal is the leading company working at the intersection of AI, computational biology, and genetic engineering for both de-extinction and species preservation,” Walter, CEO of TWG Globa, said in a news release. “Colossal has assembled a world-class team that has already driven, in a short period of time, significant technology innovations and impact in advancing conservation, which is a core value of TWG Global.”

Well-known genetics researcher George Church, co-founder of Colossal, calls the startup “a revolutionary genetics company making science fiction into science fact.”

“We are creating the technology to build de-extinction science and scale conservation biology,” he added, “particularly for endangered and at-risk species.”

View All Listings